Kurtz, Jean-Emmanuel; Pujade-Lauraine, Eric; Oaknin, Ana; Belin, Lisa; Grimm, Christoph; Kocián, Roman; Denys, Hannelore; Rosengarten, Ora-S; Follana, Philippe; Sehouli, Jalid; Martínez-García, Jerónimo; Alexandre, Jérôme; Hardy-Bessard, Anne-Claire; Frenel, Jean-Sébastian; Sabatier, Renaud; Gladieff, Laurence; De-la-Motte-Rouge, Thibault; Bonichon-Lamichhane, Nathalie; Kalbacher, Elsa; Heitz, Florian; Kurtz, J-E; Abadie-Lacourtoisie, S; Abdeddaim, C; Affi, R; Alexandre, J; Augereau, P; Avenin, D; Azemar, M; Baba-Hamed, N; Bally, O; Bazan, F; Boughalem, E; Brachet, P-E; Cappiello-Bataller, MA; Castanie, H; Chaigneau, L; Comte, A; Cottu, PH; De-la-Motte-Rouge, T; D'Hondt, V; Dillies-Legrain, AF; Extra, J-M; Frenel, JS; Freyer, G; Hardy-Bessard, A-C; Kaminsky, M-C; Lotz, J-P; Moulin, J-F; Mouret-Reynier, M-A; Ray-Coquard, I; De-la-Mothe, P-Regnault; Vano, YA; You, B; Grischke, E-M; Park-Simon, T-W; Alarcon, JD; Herrero, A-Alonso; García, J-Martínez; Sevelda, U
(AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), 2026-07)
PURPOSE Previously reported results from the placebo-controlled double-blind randomized phase III ATALANTE/ENGOT-ov29 trial (ClinicalTrials.gov identifier: NCT02891824 ) showed that progression-free survival improvement ...